Literature DB >> 19207170

Study of coagulation function in thawed apheresis plasma for photochemical treatment by amotosalen and UVA.

N de Valensart1, A Rapaille, E Goossenaerts, D Sondag-Thull, V Deneys.   

Abstract

BACKGROUND AND OBJECTIVES: Photochemical treatment (PCT) based on amotosalen and ultraviolet A light (UVA) demonstrated a wide range of pathogen inactivation. However, coagulation proteins are affected by this treatment. The aim of this study was to evaluate the coagulation parameters in apheresis plasma units after thawing and processing by PCT.
MATERIALS AND METHODS: Thirty apheresis plasma units were rapidly frozen at </= -30 degrees C after collection. Plasma units were thawed after 7 days for PCT with amotosalen and UVA light. Treated apheresis units were refrozen and stored at </= -30 degrees C for 1 month. Samples were collected for each plasma units at several times of process. Coagulation times (prothrombin time, activated partial thromboplastin time), coagulation factors (fibrinogen, Factor [F] II, FV, FVII, FVIII, FIX, FX, FXI), prothrombin fragments 1 and 2, antithrombotic proteins (protein C, protein S, antithrombin) and total protein content were measured. Functionality of ADAMTS-13 was also tested.
RESULTS: After thawing, coagulation times were slightly increased and a decrease of FV, FVIII and protein C activity was found. The mean recovery for all proteins, except one, ranged from 81% to 97% of the baseline activity in plasma units after thawing and PCT. FVIII was more affected with a mean recovery of 69 +/- 8%. ADAMTS-13 function was also preserved after the whole process. The effect of an additional 1-month frozen storage on coagulation parameters was minimum.
CONCLUSION: Coagulation protein levels after thawing and processing of plasma by PCT with amotosalen and UVA were preserved well in the physiological ranges.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19207170     DOI: 10.1111/j.1423-0410.2008.001147.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

1.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™

Authors:  Johannes Irsch; Lily Lin
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

2.  Factor VIII and fibrinogen recovery in plasma after Theraflex methylene blue-treatment: effect of plasma source and treatment time.

Authors:  André Rapaille; Stefan Reichenberg; Tome Najdovski; Nicolas Cellier; Nicolas de Valensart; Véronique Deneys
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

3.  Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.

Authors:  Susan Yonemura; Lindsay Hartson; Taru S Dutt; Marcela Henao-Tamayo; Raymond Goodrich; Susanne Marschner
Journal:  Vox Sang       Date:  2021-04-09       Impact factor: 2.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.